To include your compound in the COVID-19 Resource Center, submit it here.

SGN-75: Additional Phase I data

Seattle Genetics reported additional data from 26 evaluable patients with confirmed CD70 expression who have received at least

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE